by Fred Dumais | Nov 24, 2021 | News Release
MONTREAL, QUEBEC, November 24, 2021 – Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo Pharma” or the “Company”), a Canadian pharmaceutical company, is pleased to announce that in connection with its previously announced bought deal private placement of...
by Fred Dumais | Nov 24, 2021 | News Release
MONTREAL, QUEBEC, November 24, 2021 – Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo Pharma” or the “Company”), a Canadian pharmaceutical company, today announced that it has entered into an agreement with Desjardins Capital Markets, as lead underwriter...
by Fred Dumais | Nov 15, 2021 | News Release
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR REDESCA™ AND REDESCA HP™ IN QUEBEC Public reimbursement coverage reaches 9 Provinces in Canada Canadian private health plan coverage now exceeding 90% MONTREAL, QUEBEC , November 15, 2021 – Valeo Pharma Inc....
by Fred Dumais | Nov 3, 2021 | News Release
First provincial public listing secured for both asthma medications Additional provincial public reimbursement coverage expected to follow soon85% private payer health plan coverage across Canada MONTREAL, QUEBEC , November 3, 2021 – Valeo Pharma Inc. (CSE:VPH, OTCQB:...
by Fred Dumais | Oct 13, 2021 | News Release
VALEO PHARMA OBTAINS LISTINGS FOR REDESCA FROM TWO GPO REPRESENTING 700 HOSPITALS AND HEALTHCARE FACILITIES ACROSS CANADA 2 Group Purchasing Organizations (GPO) listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products The 2...
by Fred Dumais | Oct 5, 2021 | News Release
VALEO PHARMA COMPLETES NEGOTIATIONS WITH PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® Agreement to provide framework to participating jurisdictions in support of provincial public listings and reimbursements of both drugs...
